Rapid and complete bioavailability of antidotes for organophosphorus nerve agent and cyanide poisoning in minipigs after intraosseous administration

Ann Emerg Med. 2012 Oct;60(4):424-30. doi: 10.1016/j.annemergmed.2012.05.013. Epub 2012 Jun 26.

Abstract

Study objective: Management of chemical weapon casualties includes the timely administration of antidotes without contamination of rescuers. Personal protective equipment makes intravenous access difficult but does not prevent intraosseous drug administration. We therefore measured the systemic bioavailability of antidotes for organophosphorus nerve agent and cyanide poisoning when administered by the intraosseous, intravenous, and intramuscular routes in a small study of Göttingen minipigs.

Methods: Animals were randomly allocated to sequentially receive atropine (0.12 mg/kg by rapid injection), pralidoxime (25 mg/kg by injection during 2 minutes), and hydroxocobalamin (75 mg/kg during 10 minutes) by the intravenous or intraosseous route, or atropine and pralidoxime by the intramuscular route. Plasma concentrations were measured for 6 hours to characterize the antidote concentration-time profiles for each route.

Results: Maximum plasma concentrations of atropine and pralidoxime occurred within 2 minutes when administered by the intraosseous route compared with 8 minutes by the intramuscular route. Maximum plasma hydroxocobalamin concentration occurred at the end of the infusion when administered by the intraosseous route. The mean area under the concentration-time curve by the intraosseous route was similar to the intravenous route for all 3 drugs and similar to the intramuscular route for atropine and pralidoxime.

Conclusion: This study showed rapid and substantial antidote bioavailability after intraosseous administration that appeared similar to that of the intravenous route. The intraosseous route of antidote administration should be considered when intravenous access is difficult.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antidotes / administration & dosage*
  • Antidotes / pharmacokinetics
  • Antidotes / therapeutic use
  • Atropine / administration & dosage
  • Atropine / blood
  • Atropine / pharmacokinetics
  • Atropine / therapeutic use
  • Biological Availability
  • Chemical Warfare Agents / poisoning*
  • Cyanides / antagonists & inhibitors
  • Cyanides / poisoning*
  • Hydroxocobalamin / administration & dosage
  • Hydroxocobalamin / blood
  • Hydroxocobalamin / pharmacokinetics
  • Hydroxocobalamin / therapeutic use
  • Infusions, Intraosseous / methods*
  • Infusions, Intravenous
  • Injections, Intramuscular
  • Male
  • Organophosphate Poisoning / drug therapy*
  • Pralidoxime Compounds / administration & dosage
  • Pralidoxime Compounds / blood
  • Pralidoxime Compounds / pharmacokinetics
  • Pralidoxime Compounds / therapeutic use
  • Swine
  • Swine, Miniature
  • Time Factors

Substances

  • Antidotes
  • Chemical Warfare Agents
  • Cyanides
  • Pralidoxime Compounds
  • Atropine
  • pralidoxime
  • Hydroxocobalamin